Biogen, UCB lupus drug dapirolizumab pegol meets phase 3 goal (BIIB:NASDAQ)
· seekingalpha.com
UCB & Biogen’s dapirolizumab pegol hits Phase 3 lupus endpoint, improving BICLA response and safety signals.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...